084990:KOSDAQ
Helixmith Co Ltd
₩3,985.00
arrow_upward
+0.38%(+15.00) 1D
Oct 20, 10:11:30 AM GMT+9 · KRW
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 084990...
Open
₩4,000
High
₩4,300
Low
₩3,950
Mkt. cap
182.76B
Avg. vol.
396.68K
Volume
228.78K
52-wk high
₩9,960
52-wk low
₩2,725
EPS
-₩35
Shares outstanding
46.09M
No. of employees
38
Open
₩4,000
High
₩4,300
Low
₩3,950
Mkt. cap
182.76B
Avg. vol.
396.68K
Volume
228.78K
52-wk high
₩9,960
52-wk low
₩2,725
EPS
-₩35
Shares outstanding
46.09M
No. of employees
38
News stories
From web sources and news partners
TheStreet
·
1 hour ago
Sam Stovall’s S&P 500 outlook offers hope for 2027
Action Forex
·
6 minutes ago
The S&P 500 Is on a Dangerous Path
Investing.com
·
4 hours ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
TradingView
·
5 hours ago
There is no fundamental reason for stocks’ reversal, says SA analyst
Profile
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
About Helixmith Co Ltd